Objective-To examine whether changes in canceilous bone turnover and resorption cavity depth contribute to bone loss in patients with non-steroid treated rheumatoid arthritis. Methods-Iliac crest biopsies were obtained from 37 patients with non-steroid treated rheumatoid arthritis, 13 male and 24 female, aged 37-71 years. Bone turnover and resorption cavity characteristics were quantitatively assessed using semiautomated computerised techniques. Results-When compared with age-and sex-matched control values, there was a significant reduction in bone formation rate at tissue level and activation frequency (P < 0.001) in the patient group. The eroded perimeter, mean and maximum eroded depth and cavity area were also significantly reduced (P < 0'01, <0.005, <0 001 and <0 005 respectively).
Both localised and generalised bone loss have been described in association with rheumatoid arthritis.'l Generalised osteopenia has been reported in both steroid treated and nonsteroid treated patients and there is some evidence that fracture risk may also be increased, particularly in the former group.8 9 The pathogenesis of bone loss in nonsteroid treated patients has not been clearly defined; possible pathogenetic factors include reduced physical activity,10-'2 systemic effects of the disease itself and drugs used in its treatment. 4 9 Previous studies have demonstrated a reduced cancellous bone area in iliac crest biopsies obtained from patients with rheumatoid arthritis '8-20 reduction in calculated resorption depth was also shown.2' These data indicate that remodelling imbalance contributes to the observed bone loss; however, it is uncertain whether increased bone turnover also plays a role. In this study we have assessed bone turnover in 37 patients with non-steroid treated rheumatoid arthritis. In addition, resorption cavity depth has been directly measured using a computerised technique.
Methods

PATIENTS AND CONTROL SUBJECTS
Thirty seven patients with definite or classic rheumatoid arthritis who had enrolled into a trial of second-line therapy were studied, 13 men aged 37-62 years (mean 50O 1) and 24 women aged 35-71 years (mean 55-3). Nineteen of the women were postmenopausal. The median duration of disease was four years (range 1-25) and none had received systemic steroid therapy at any time. Most patients were taking nonsteroidal anti-inflammatory drugs and all were receiving second-line therapy (penicillamine, hydroxychloroquine, auranofin or intramuscular sodium aurothiomalate); none was receiving methotrexate. No patient was housebound or restricted to a wheelchair and patients with a history of gastrointestinal disease or surgery, liver disease, chronic renal disease or endocrine disease were excluded from the study. All patients gave informed written consent for the bone biopsy and permission to carry out the study was granted by the local ethical committee. The modified Health Assessment Questionnaire (HAQ)22 ranged between 0 and 3 (mean I O 10); Steinbroker Class23 was 1 in four patients, 2 in 26 patients and 3 in seven patients.
Control values were obtained from a subset of a group of 57 healthy subjects, details of whom have been described previously.24 These subjects gave informed written consent to undergo bone biopsy at the same time as a minor surgical procedure requiring general anaesthetic and the study was approved by the local ethical committee. Indices of bone formation were assessed in 37 patients and resorption cavity characteristics in 36; control data for the former were available in 40 subjects, 17 Gieson counterstain, or 1% toluidine blue (pH 4 2). Unstained sections, 15 p.m thick, were also prepared for fluorescence microscopy. All patients received two, time-spaced doses of demethylchlortetracycline before the biopsy (300 mg twice daily on days 1, 2, 13 and 14), the biopsy being performed 3-5 days after the last dose.
Tetracycline-based measurements Histomorphometric measurements in patients with rheumatoid arthritis were made using a 'Digicad' digitising tablet and cursor with an LED point light source (Kontron Ltd) and an Olympus BHS-BH2 binocular transmitted light microscope with a BH2-DA drawing attachment (Olympus Optical Co, London). Mineralised bone perimeter was measured on unstained sections viewed by fluorescence microscopy at X 156 magnification, the labelled perimeter being traced with the cursor LED. The mineralising perimeter (M.Pm/B.Pm; %) was calculated as the double-labelled surface plus half the single-labelled surface. The mean distance between tetracycline labels was measured directly at X 312 magnification using the digitising tablet and cursor. Measurements were made at approximately four equidistant points along double labels; 3-4 sections from each biopsy were used for these measurements.
Because of fading of tetracycline fluorescence on the control sections, which had been cut 10 or more years previously and the unavailability of sufficient embedded material in most biopsies to enable preparation of new sections, the original control data which had been obtained using an eye-piece graticule and micrometer, were used. To evaluate possible intermethod differences, a comparison of the two techniques was performed by one observer in six biopsies obtained from postmenopausal women who formed part of a separate study. The mean difference between the two methods was 0-36% for single-labelled and 0-02% for double-labelled surface (P = NS). For measurement of interlabel distance, a systematic difference was found between the two methods, the eye-piece micrometer producing a significantly higher value than the semi-automated method (P < 0-01). Comparison of patients with control subjects revealed a significant reduction in mineralising perimeter (P < 0 00 1), bone formation rate at tissue level (P < 0 001) and activation frequency (P < 0-00 1). Eroded surface was significantly reduced in the patient group (P < 0 01), with a non-significant reduction in the number of 33 42 have been shown to correlate with bone loss and reduced mobility may also play a role.'3 43 In addition, non-steroidal disease modifying and anti-inflammatory agents may affect osteoblast function; the 
